Pharmacokinetic Profiling of Unlabeled Magnetic Nanoparticles Using Magnetic Particle Imaging as a Novel Cold Tracer Assay.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39591368.
- Also identified by DOI 10.1021/acs.nanolett.4c03553 and PMC identifier 11646110.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We present a magnetic particle imaging (MPI)-based assay for calculating the blood half-life and tissue uptake of magnetic nanoparticles (MNPs) without the need of labeling them. Dual-catheterized rats received 2.0 mg Fe of Synomag<sup>®</sup>-D70, Synomag<sup>®</sup>-D50, ferucarbotran, and Feraheme<sup>®</sup> by femoral vein injection. The MPI signal of blood samples drawn from the femoral artery at various time points was then measured. Synomag<sup>®</sup>-D70 exhibited biexponential clearance with half-lives of 3.2 and 31.2 min, Synomag<sup>®</sup>-D50 a monoexponential clearance (<i>t</i><sub>1/2</sub> = 11.4 min), ferucarbotran a biexponential clearance (<i>t</i><sub>1/2</sub> = 2.4 and 10.8 min), and Feraheme<sup>®</sup> a biexponential clearance (<i>t</i><sub>1/2</sub> = 60.9 and 4.5 min). MPI of perfused tissues showed MNPs primarily localizing in the spleen, liver, and lymph nodes. Spectrophotometric/chemical iron detection proved unreliable due to residual iron from endogenous blood. The MPI assay is a sensitive and specific method for evaluating the pharmacokinetics of existing MNP formulations and those in the pipeline, with exquisite sensitivity for ultrashort half-lives.
Medical subject headings
- Magnetite Nanoparticles